SCHEMBL7472641

SCHEMBL7472641

CCCCN(CCCC)c1cccc(OCC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MTNR1A P48039 4/20 0.44
MTNR1B P49286 4/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 2/20 0.43
THRB P10828 2/20 0.43
KMT2A Q03164 2/20 0.43
CETP P11597 1/20 0.43
MAPK1 P28482 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
TSHR P16473 3/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GUSB P08236 1/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8300202 0.95 TP53 (0.46) TP53CYP3A4MTNR1AMTNR1BALDH1A1
SCHEMBL8295925 0.90 TSHR (0.49) MTNR1AMTNR1BTHRBKMT2ACYP1A2
SCHEMBL8664850 0.85 MTNR1A (0.58) MTNR1AMTNR1B
SCHEMBL12862530 0.83 ALDH1A1 (0.49) TP53CYP3A4ALDH1A1KDM4EMEN1
SCHEMBL10890808 0.83 CYP3A4 (0.47) TP53CYP3A4MTNR1AMTNR1BALDH1A1
SCHEMBL31339101 0.82 ALDH1A1 (0.55) TP53CYP3A4ALDH1A1KDM4EMEN1
SCHEMBL1760671 0.82 ALDH1A1 (0.55) TP53CYP3A4ALDH1A1KDM4EMEN1
SCHEMBL19495909 0.82 MTNR1A (0.56) MTNR1AMTNR1B
SCHEMBL8664260 0.82 ALDH1A1 (0.45) CYP3A4MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL11671072 0.82 LMNA (0.46) ALDH1A1KDM4EMEN1THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-0664292-B1 A phtalide compound and a near infrared absorber and a recording material each comprising the same compound YAMAMOTO CHEMICALS INC (JP) 2002-06-19 EP disclosed
US-5627287-A COLORLESS YAMAMOTO CHEMICALS, INC. (JP) 1997-05-06 US disclosed
EP-0664292-A1 A phtalide compound and a near infrared absorber and a recording material each comprising the same compound YAMAMOTO CHEMICALS, INC. (JP) 1995-07-26 EP disclosed
EP-0377406-B1 PRESSURE-SENSITIVE OR HEAT-SENSITIVE RECORDING MATERIAL CIBA-GEIGY AG (CH) 1993-06-09 EP disclosed
US-5013707-A Pressure- or heat-sensitive recording material CIBA-GEIGY CORPORATION (US) 1991-05-07 US disclosed
EP-0377406-A1 Pressure-sensitive or heat-sensitive recording material CIBA-GEIGY AG (CH) 1990-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 TP53 4310/4885CYP3A4 1260/4885MTNR1A 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.